Singapore: Suven Life Sciences received three product patents, two from Eurasia and one from Canada for its new chemical entities (NCEs), which can be used to treat disorders associated with neurodegenerative diseases. The patents are valid through 2027.

The granted claims of the patents include the class of selective 5-HT compounds, discovered by Suven and are being developed as therapeutic agents. The compounds are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and schizophrenia.

With these new patents, Suven has a total of 10 granted product patents from Canada and 12 granted product patents from Eurasia. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase I or phase II.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally" said Mr Venkat Jasti, CEO, Suven.

The company has 12 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and schizophrenia.